REAL-WORLD CHARACTERISTICS AND TREATMENT PATTERNS OF PATIENTS TREATED WITH TALAZOPARIB + ENZALUTAMIDE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN THE US COMMUNITY ONCOLOGY SETTING

Author(s)

Andrew Osterland, PharmD, MS1, Melissa Kirker, PharmD, MPH2, Saamir Pasha, MPH1, Wei Dai, MS1, Suvina Amin, BSc, MPH2, Neo Su, MPH, MS, PharmD2, Benjamin Li, PhD2, Sarah Hanson, MD, PhD2, Gregory Patton, MD, MS, MBA1, Manojkumar Bupathi, MD3.
1Ontada, Boston, MA, USA, 2Pfizer, New York, NY, USA, 3Rocky Mountain Cancer Centers, Littleton, CO, USA.
OBJECTIVES: Talazoparib plus enzalutamide (T+E) was FDA-approved in June 2023 as treatment for metastatic castration-resistant prostate cancer (mCRPC) harboring alterations in the homologous recombination repair pathway (HRRm). Given this recent approval, further understanding of real-world patients and practice patterns of T+E is needed.
METHODS: This was a retrospective observational cohort study of patients initiating T+E for mCRPC (index) between 6/20/2023-12/31/2024 in The US Oncology Network or non-Network practices. Baseline characteristics within 60 days pre-index, HRRm results and prostate cancer treatment history through the end of follow-up (3/31/2025) were abstracted from charts. Descriptive analyses were stratified by prior androgen receptor pathway inhibitor(s) (ARPi) and/or docetaxel.
RESULTS: Overall, 52 patients were included with median (IQR) age of 73 (65-80) years and median (IQR) 8 (5-12) months follow-up. Among patients with available data at baseline, the median (IQR) PSA was 11.9 (4.8-53.4) ng/mL, most patients were ECOG 0-1 (89% of n=36), Gleason ≥8 (79% of n=34) and had high-volume disease (77% of n=52). HRRm were documented in 40 (77%) patients, of which n=19 had BRCAm only, n=18 had non-BRCAm only, and n=3 had both BRCAm/non-BRCAm. The most common HRRm were BRCA2 (n=18), CDK12 (n=7), ATM and CHEK2 (n=5, each). Prior to T+E, 44 (85%) patients had prior treatment with ARPi, of which 28 (54%) patients had received ARPi+docetaxel. High-volume disease was documented in 37 (84%) patients with prior ARPi, and 3 (38%) patients without prior ARPi. T+E was initiated as the 1st, 2nd, and 3rd or later regimen for mCRPC in 30 (57%), 8 (15%) and 14 (27%) patients, respectively.
CONCLUSIONS: This is the first real-world study of patient characteristics and use of T+E for mCRPC in the community oncology setting. Most patients had high metastasis burden, prior treatment with ARPi, and HRRm. This study will inform future real-world effectiveness analyses of T+E for mCRPC with HRRm.

Conference/Value in Health Info

2026-05, ISPOR 2026, Philadelphia, PA, USA

Value in Health, Volume 29, Issue S6

Code

HSD10

Topic

Health Service Delivery & Process of Care

Disease

SDC: Oncology, STA: Personalized & Precision Medicine

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×